Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection

New England Journal of Medicine

Volumn 338, Issue 13, 1998, Pages 853-860

  Palella Jr , Frank J ^a   Delaney, Kathleen M ^b   Moorman, Anne C ^c   Loveless, Mark O ^d   Fuhrer, Jack ^e   Satten, Glen A ^c   Aschman, Diane J ^b   Holmberg, Scott D ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Hlth Res Netwk Apache Med Syst   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MORBIDITY; MORTALITY; MYCOBACTERIOSIS; OPPORTUNISTIC INFECTION; OUTCOMES RESEARCH; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; INCIDENCE; INSURANCE, HEALTH; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PNEUMONIA, PNEUMOCYSTIS; UNITED STATES;

EID: 2642709177     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199803263381301     Document Type: Article

References (27)

1. Ho DO, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
2. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6.
3. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-9.
4. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
5. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91.
6. Bartlett JA, Benoit SL, Johnson VA, et al. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:161-72.
7. Gulick R, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC). In: Supplement to the XI International Conference on AIDS, Vancouver, B.C., July 7-12, 1996. Vancouver, B.C.: XI International Conference on AIDS Society, 1996:19. abstract.
8. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
9. Ho DD. Viral counts count in HIV infection. Science 1996;272:1124-5.
10. Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997;126:929-38.
11. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997;126:939-45.
12. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
13. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
14. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
15. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nat Med 1996;2:625-9.
16. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-8.
17. Update: trends in AIDS incidence, deaths, and prevalence - United States, 1996. MMWR Morb Mortal Wkly Rep 1997;46:165-73.
18. Chaisson MA, Berenson L, Li W, Schwartz S, Mojica B, Hamburg M. Declining AIDS mortality in New York City (NYC). In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22-26, 1997. Washington, D.C.: IDSA Foundation for Retrovirology and Human Health, 1997:133. abstract.
19. Mouton Y, Cartier F, Dellamonica P, et al. Dramatic cut in AIDS defining events and hospitalization for patients under protease inhibitors (P.I) and tritherapies (TTT) in 9 AIDS référence centers (ARC) and 7,391 patients. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 22-26, 1997 Washington, D.C.: IDSA Foundation for Retrovirology and Human Health, 1997:208. abstract.
20. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997;336:1531-2.
21. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997;349:1294.
22. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996;334:701-6.
23. Markson LE, Cosler LE, Turner BJ. Implications of generalists' slow adoption of zidovudine in clinical practice. Arch Intern Med 1994;154:1497-504.
24. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996;276:146-54.
25. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;124:1019-30.
26. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81.
27. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society - USA panel. JAMA 1997;277:1962-9.